novavax stock price: market overview
Novavax stock price
This article explains the novavax stock price, what drives its movements, where to find reliable live and historical quotes, and the measurable metrics investors and traders commonly track. Readers will learn how trading details, corporate events, clinical and regulatory news, market microstructure, and short interest can affect NVAX. The guide stays neutral and factual and points to trusted public data sources and Bitget as a recommended trading venue and Bitget Wallet for custody needs.
Company and stock overview
Novavax, Inc. is a biotechnology company focused on vaccine development and production. In public markets, the novavax stock price refers to the quoted market price for Novavax common shares, traded under the ticker NVAX on a major U.S. exchange. Owning NVAX represents equity ownership in Novavax, subject to common share rights and any corporate governance terms recorded in the company’s charter and SEC filings.
Key points:
- The novavax stock price quotes the value of a single common share in U.S. dollars.
- NVAX is a biotechnology/economics-of-healthcare name sensitive to clinical, regulatory, and partnership news.
- Shareholders are exposed to company performance, sector dynamics, and broader market moves.
Trading details
Understanding the trading plumbing behind the novavax stock price helps interpret quotes and intraday swings. Typical trading details for NVAX include:
- Exchange: NVAX trades on a U.S. national exchange; prices are quoted in U.S. dollars.
- Ticker symbol: NVAX.
- Trading sessions: regular U.S. session (typically 09:30–16:00 ET); pre‑market and after‑hours sessions also report trades that can move the novavax stock price outside regular hours.
- Shares outstanding, float and market capitalization change over time; these items materially affect market cap calculations for the novavax stock price.
Because shares outstanding and float can change after equity financings, secondary offerings, or conversions, always check the company’s investor relations statement or filings for the most recent totals when calculating market capitalization from the novavax stock price.
Live price and quote sources
Public quote providers commonly used to view the novavax stock price include real‑time and delayed sources. Common places to check quotes and basic metrics are:
- Yahoo Finance
- Google Finance
- TradingView
- MarketWatch
- Major retail broker platforms and mobile broker apps
- Company Investor Relations pages for official notices and stock details
Note on latency: many free public pages show delayed or slightly aggregated quotes; professional feeds provide true real‑time data. When watching the novavax stock price for execution, use a trading venue or broker that offers real‑time market data and execution. For custody or on‑chain wallet references related to tokenized instruments, consider Bitget Wallet.
Historical price overview
Historical price data for the novavax stock price is available at daily, weekly, monthly and intraday granularity via market data vendors and the company’s historical price tables. Historical records let users examine volatility, returns from different start dates, and milestone levels.
Major historical milestones commonly cited for Novavax include a large run‑up during the pandemic‑era vaccine optimism and later periods of volatility tied to clinical/regulatory developments and capital markets activity. Sources that preserve long price series and allow downloads include public finance portals and data vendors that maintain multi‑year historical series for the novavax stock price.
Price timeline and notable periods
A concise timeline of notable periods that affected the novavax stock price:
- 2020–2021: Vaccine‑related enthusiasm drove a sharp increase in the novavax stock price, reaching multi‑hundred dollar levels at peaks amid strong investor interest in vaccines.
- 2022–2024: Following peak valuation periods, NVAX experienced steep declines and volatile rebounds as vaccine demand, regulatory outcomes, and corporate financing altered expectations.
- 2025–2026: Price movements continued to react to discrete clinical updates, regulatory interactions, partnership or licensing outcomes, and capital markets activity including equity financings and short interest dynamics.
These periods illustrate how clinical outcomes and capital markets activity can cause large percentage moves in the novavax stock price over relatively short horizons.
Recent price movements and key drivers
Short‑term changes in the novavax stock price typically follow a small set of observable events and market forces:
- Company news: results from clinical trials, regulatory approvals or denials, emergency use authorizations, manufacturing updates, or strategic partnerships that directly alter revenue expectations.
- Financial releases: quarterly earnings, guidance, liquidity disclosures and equity financings can change investor perceptions and the novavax stock price.
- Sector and regulatory environment: vaccine market dynamics, competing product launches, or policy shifts on procurement can move NVAX.
- Macro factors: interest rates, general market risk appetite and sector rotation affect healthcare and biotech stocks, including the novavax stock price.
- Market microstructure: heavy short interest, low float, or thin order books can magnify intraday volatility of the novavax stock price.
Important measurable recent data (reporting snapshot):
- As of January 27, 2026, according to Benzinga, the quoted price used in their snapshot for NVAX was $9.56.
- As of the same report, Benzinga noted that Novavax Inc.'s short interest had risen by 4.06% since the last report; there were approximately 54.72 million shares sold short, equal to 33.8% of the reported float.
- Benzinga reported it would take about 17.0 days to cover the current short positions based on trading volume, and that the peer group average for short interest as a percentage of float was about 12.34%.
These short interest figures are directly relevant to the novavax stock price: elevated short interest can increase downside pressure in neutral or negative news flows and may also increase the potential for abrupt squeezes if supply tightens or positive catalysts arrive.
Financial metrics that influence stock price
Market participants watching the novavax stock price commonly track the following quantifiable fundamental metrics:
- Revenue: topline growth or declines tied to product sales, government contracts, or royalties.
- Net income (or loss) and EPS: profitability or continued losses are a primary input to valuation.
- Cash and short‑term investments: cash runway and liquidity affect dilution risk through equity raises, which in turn can pressure the novavax stock price.
- Debt and liabilities: leverage can influence downside risk perceptions.
- Free cash flow: ability to self‑fund operations reduces dependence on dilutive financings.
For biotech companies like Novavax that may have episodic revenue related to vaccine cycles and may report negative earnings over multiple periods, many valuation metrics must be interpreted differently than for stable, profitable companies. That context is essential when comparing the novavax stock price against traditional valuation ratios.
Valuation and market ratios
Common ratios and how to treat them for NVAX and similar biotech firms:
- Price/Earnings (P/E) and Forward P/E: when a company reports negative earnings, P/E is not meaningful; analysts may use adjusted or pro‑forma metrics or rely more on price/sales or discounted cash flow models.
- Price/Sales (P/S): useful when revenue is present but earnings are negative — provides a topline‑based multiple to gauge market pricing relative to sales.
- Price/Book (P/B): can be informative if book value is meaningful, but many biotech firms are asset‑light in terms of tangible book value.
Because the novavax stock price can swing on binary clinical and regulatory outcomes, market‑implied multiples often reflect option‑like pricing tied to future approvals or large contracts rather than stable operating earnings.
Analyst coverage and price targets
Institutional analysts and sell‑side firms track NVAX and publish ratings and price targets. Analyst coverage affects the novavax stock price through revisions to revenue forecasts, probability‑weighted outcomes for regulatory approvals, and updated discount rates.
Reader guidance:
- Monitor consensus ratings and the range of price targets to understand the spread of professional views.
- Watch for substantial target revisions on key clinical or regulatory news days, as these revisions often move the novavax stock price meaningfully.
No rating or target in this guide should be taken as investment advice; the information is for background and informational purposes only.
Trading statistics and market microstructure
Metrics that traders use to assess the novavax stock price environment include:
- Average daily trading volume: measures liquidity and how easily position sizes can be executed without moving the novavax stock price.
- Intraday volatility: measured by intraday range statistics and indicators like average true range (ATR); higher volatility means larger potential price swings.
- Bid/ask spread: wider spreads increase transaction costs and slippage when trading the novavax stock price.
- Short interest and days to cover: large short interest (reported at 33.8% of float as of January 27, 2026, per Benzinga) can influence volatility and upside squeeze risk for the novavax stock price.
- Institutional vs. insider ownership: high institutional ownership can stabilize or destabilize pricing depending on flows; insider transactions may provide signal data for market participants.
Because the novavax stock price can be sensitive to order book depth and block trades, execution strategy and awareness of liquidity are important for larger traders.
Technical analysis perspective
Many traders apply technical indicators to the novavax stock price for timing and risk management. Common tools include:
- Moving averages (e.g., 50/200‑day): for trend identification and crossover signals that have short‑ and intermediate‑term significance for the novavax stock price.
- Support and resistance zones: historical price levels where the novavax stock price has reversed or consolidated.
- Relative Strength Index (RSI) and momentum indicators: used to detect overbought/oversold conditions in the novavax stock price.
- Volume analysis and on‑balance volume: to confirm moves in the novavax stock price with participation levels.
Charting platforms and broker chart tools provide customizable indicators to analyze the novavax stock price; look for platforms that offer historical overlays and multiple time frames.
Corporate actions and capital markets activity
Corporate actions often change supply dynamics for the novavax stock price:
- Secondary offerings and ATM programs: can increase share count and exert downward pressure on the novavax stock price if new shares enter the market.
- Convertible instruments or warrants: upon conversion or exercise, additional share issuance can affect the novavax stock price.
- Share buybacks: reduce float and can support the novavax stock price if executed.
- Insider transactions and lock‑ups: insider selling or expiration of lock‑ups after financings may increase available tradable supply, influencing the novavax stock price.
Always consult the company’s SEC filings for details on authorized share increases, registration statements, or prospectuses for quantifiable impacts on the novavax stock price.
Regulatory, clinical, and industry risks
For a vaccine developer, the primary drivers of sudden moves in the novavax stock price are clinical and regulatory outcomes and competitive dynamics. Key risk areas include:
- Clinical trial results: positive or negative endpoints can cause immediate, large moves in the novavax stock price.
- Regulatory approvals or denials: agency decisions materially affect market expectations for future revenue and thus the novavax stock price.
- Safety signals and adverse events: post‑approval safety reports or recalls can drive pronounced declines in the novavax stock price.
- Intellectual property and licensing disputes: patent challenges or lost licensing deals can alter long‑term revenue prospects and the novavax stock price.
- Competitive entrants: new vaccines from large pharmaceutical peers or shifting procurement policies can change market share assumptions underlying the novavax stock price.
These risks make the novavax stock price more event‑driven than many diversified industrial or consumer names.
Events calendar affecting price
Items to watch on a public company events calendar that commonly move the novavax stock price:
- Quarterly earnings releases and conference calls.
- Clinical trial milestone dates and topline result announcements.
- Regulatory advisory committee meetings and decision dates.
- Investor presentations at major conferences and partnership announcements.
- SEC filings that disclose financings, share issuance or insider transactions.
Keep an events calendar and set alerts for the novavax stock price around these items, as volatility often spikes on event days.
Comparative peers and sector context
Novavax operates in the vaccine and broader biotech sector. Peer companies frequently referenced when contextualizing the novavax stock price include large and mid‑cap vaccine developers and biotech firms that compete in product space or share similar financing profiles. Peer performance and sector rotation can influence investor appetite for the novavax stock price.
When comparing NVAX to peers, analysts look at revenue exposure to vaccine sales, pipeline comparatives, balance sheet strength and recent judicial or regulatory rulings that may affect pricing power.
How to interpret NVAX quotes safely
Guidance for interpreting the novavax stock price:
- Distinguish regular session last trade from pre‑market/after‑hours prints; the novavax stock price may differ across sessions.
- Understand bid/ask: the quoted last price is the most recent trade, but the bid and ask show current buying and selling interest that affect execution.
- Beware of delayed quotes: some public pages show quotes delayed by 15 minutes or more; for execution use live market feeds.
- Anticipate slippage: in low liquidity conditions, the executed price for the novavax stock price may differ from the displayed quote when placing market orders.
For secure custody and trading access, consider Bitget and Bitget Wallet for order execution and digital asset management consistent with your operational needs.
Historical data and reference sources
Authoritative places to obtain historical novavax stock price series and corporate disclosures include the company's investor relations materials and financial data vendors that maintain long‑term price histories. Data vendors frequently allow CSV downloads for research and backtesting purposes. Typical providers used by market participants include major finance portals, charting platforms, and the company’s filings on the official regulator site.
See also
- Novavax (company) profile
- Vaccine market dynamics
- U.S. stock market quotes and market structure
References
The following public data providers and news outlets were referenced for structuring this overview and for the short interest snapshot included above:
- Yahoo Finance (NVAX quote and fundamentals)
- Novavax Investor Relations (official stock details and filings)
- TradingView (charts and technical tools)
- Google Finance (price snapshot)
- Macrotrends (historical price series)
- Finviz (snapshot metrics)
- CNN Markets (quotes & commentary)
- Robinhood stock page (retail quote)
- MarketWatch (quote & market commentary)
- Benzinga (short interest and market news; short interest figure cited below)
Notable reporting snapshot used in this guide:
- As of January 27, 2026, according to Benzinga, Novavax Inc.'s short interest as a percent of float had risen 4.06% since its last report. The report stated there were 54.72 million shares sold short, equivalent to 33.8% of the float, and that it would take approximately 17.0 days to cover those short positions based on trading volume. Benzinga also reported a peer‑group average short interest of approximately 12.34%.
External links
For live quotes, filings and historical data, consult the company investor relations page, the official regulator filing repository, and major finance portals and charting platforms listed in References. For trading and custody, consider Bitget for execution and the Bitget Wallet for asset management.
Notes on scope and updates
Stock price pages and metrics such as the novavax stock price, short interest, shares outstanding, and market cap change frequently. This guide is intended as an educational and reference overview. For the latest real‑time quotes, official filing numbers, and actionable execution, consult live market data and the company’s SEC filings.
How to use this page and next steps
If you are monitoring the novavax stock price closely:
- Set alerts for clinical, regulatory, and earnings dates on your calendar.
- Track short interest updates and changes in float or outstanding shares in SEC filings.
- Use a trading venue with sound execution and real‑time data; consider Bitget for order placement and Bitget Wallet for custody if you use Bitget services.
For deeper research, download historical price series from the listed data providers and review Novavax’s quarterly and annual reports for up‑to‑date balance sheet and pipeline information.
Further explore Bitget features to streamline your market monitoring and execution setup.
If you want a tailored one‑page summary that includes the latest live novavax stock price and a short, dated snapshot of recent metrics (short interest, last trade price, and trading volume), tell us and we will generate a dated summary based on the cited public sources. Explore Bitget to access real‑time data and execution tools.
